Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy
- PMID: 38474611
- PMCID: PMC10934406
- DOI: 10.3390/molecules29051097
Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy
Abstract
The α2A adrenergic receptor (α2A-AR) serves as a critical molecular target for sedatives and analgesics. However, α2A-AR ligands with an imidazole ring also interact with an imidazoline receptor as well as other proteins and lead to undesirable effects, motivating us to develop more novel scaffold α2A-AR ligands. For this purpose, we employed an ensemble-based ligand discovery strategy, integrating long-term molecular dynamics (MD) simulations and virtual screening, to identify new potential α2A-AR agonists with novel scaffold. Our results showed that compounds SY-15 and SY-17 exhibited significant biological effects in the preliminary evaluation of protein kinase A (PKA) redistribution assays. They also reduced levels of intracellular cyclic adenosine monophosphate (cAMP) in a dose-dependent manner. Upon treatment of the cells with 100 μM concentrations of SY-15 and SY-17, there was a respective decrease in the intracellular cAMP levels by 63.43% and 53.83%. Subsequent computational analysis was conducted to elucidate the binding interactions of SY-15 and SY-17 with the α2A-AR. The binding free energies of SY-15 and SY-17 calculated by MD simulations were -45.93 and -71.97 kcal/mol. MD simulations also revealed that both compounds act as bitopic agonists, occupying the orthosteric site and a novel exosite of the receptor simultaneously. Our findings of integrative computational and experimental approaches could offer the potential to enhance ligand affinity and selectivity through dual-site occupancy and provide a novel direction for the rational design of sedatives and analgesics.
Keywords: bitopic agonist; ensemble-based screening; molecular dynamics simulation; α2A-AR.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures








Similar articles
-
The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening.Int J Mol Sci. 2024 Jun 30;25(13):7233. doi: 10.3390/ijms25137233. Int J Mol Sci. 2024. PMID: 39000340 Free PMC article.
-
The α2A -adrenoceptor subtype plays a key role in the analgesic and sedative effects of xylazine.J Vet Pharmacol Ther. 2019 Mar;42(2):243-247. doi: 10.1111/jvp.12724. Epub 2018 Nov 11. J Vet Pharmacol Ther. 2019. PMID: 30417462
-
Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.Neuropharmacology. 2015 Dec;99:285-300. doi: 10.1016/j.neuropharm.2015.08.010. Epub 2015 Aug 6. Neuropharmacology. 2015. PMID: 26254859 Free PMC article.
-
The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.BMC Pharmacol. 2007 Dec 20;7:16. doi: 10.1186/1471-2210-7-16. BMC Pharmacol. 2007. PMID: 18096057 Free PMC article.
-
α2C-adrenoceptor modulators: a patent review.Expert Opin Ther Pat. 2011 Apr;21(4):455-81. doi: 10.1517/13543776.2011.565333. Expert Opin Ther Pat. 2011. PMID: 21413828 Review.
Cited by
-
Novel candidates synthesis of indenopyrazole, indenoazine and indenothiophene, with anticancer and in silico studies.Future Med Chem. 2024;16(14):1429-1447. doi: 10.1080/17568919.2024.2351350. Epub 2024 Jun 5. Future Med Chem. 2024. PMID: 39190476 Free PMC article.
-
Tandospirone prevents anesthetic-induced respiratory depression through 5-HT1A receptor activation in rats.Sci Rep. 2025 Jan 3;15(1):653. doi: 10.1038/s41598-024-84440-x. Sci Rep. 2025. PMID: 39753642 Free PMC article.
References
-
- Schwinn D.A., Correa-Sales C., Page S.O., Maze M. Functional effects of activation of alpha-1 adrenoceptors by dexmedetomidine: In vivo and in vitro studies. J. Pharmacol. Exp. Ther. 1991;259:1147–1152. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials